Want to see HK:2216 full AI Analyst Report?
Top Page
Broncus Holding Corp.
(2216)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.61
▼(-74.24% Downside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by very weak financial performance (severe revenue contraction, persistent losses, and ongoing cash burn). Technicals add further pressure given a clear downtrend and negative momentum signals. Valuation is not a clear positive due to loss-making earnings (negative P/E) and no dividend yield provided, while the low-leverage balance sheet is the main stabilizing factor.
Positive Factors
Low leverage / strong equity base
A very low debt load and sizable positive equity materially reduce refinancing and liquidity risk, giving management time to execute operational fixes or seek strategic options. That balance sheet flexibility supports investment or M&A optionality over the next several months without immediate solvency pressure.
Negative Factors
Severe revenue collapse
A near-total drop in revenue signals a major loss of commercial traction—whether from product withdrawal, customer loss, or regulatory/commercial issues. Restoring recurring sales will likely require substantial time, resources, and execution risk, pressuring medium-term recovery prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity base
A very low debt load and sizable positive equity materially reduce refinancing and liquidity risk, giving management time to execute operational fixes or seek strategic options. That balance sheet flexibility supports investment or M&A optionality over the next several months without immediate solvency pressure.
Read all positive factors
Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$333.10M
Dividend YieldN/A
Average Volume (3M)2.03M
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees200
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.02
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Broncus Holding Corp. Business Overview & Revenue Model
Company Description
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other internation...
How the Company Makes Money
Detailed, company-specific information on Broncus Holding Corp. (2216)’s revenue model and key revenue streams (e.g., primary product lines sold, recurring consumables, service/maintenance revenue, pricing model, geographic mix, and material partn...
Broncus Holding Corp. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 174.00K | 8.13M | 10.26M | 9.41M | 10.89M |
| Gross Profit | -917.00K | 6.14M | 7.23M | 7.32M | 8.74M |
| EBITDA | -22.68M | -18.96M | -25.06M | -30.58M | -233.31M |
| Net Income | -17.88M | -15.30M | -28.09M | -28.04M | -236.18M |
Balance Sheet | |||||
| Total Assets | 156.11M | 175.90M | 195.81M | 221.94M | 252.81M |
| Cash, Cash Equivalents and Short-Term Investments | 69.24M | 139.11M | 156.88M | 187.91M | 227.21M |
| Total Debt | 16.00K | 318.00K | 2.35M | 1.47M | 1.95M |
| Total Liabilities | 6.17M | 6.42M | 10.44M | 8.48M | 10.39M |
| Stockholders Equity | 149.94M | 169.48M | 185.37M | 213.46M | 242.42M |
Cash Flow | |||||
| Free Cash Flow | -10.04M | -10.32M | -26.84M | -31.81M | -33.38M |
| Operating Cash Flow | -10.00M | -10.00M | -26.13M | -30.95M | -31.49M |
| Investing Cash Flow | -877.29K | -25.91M | 5.49M | -87.57M | -1.75M |
| Financing Cash Flow | -4.60M | -1.02M | -1.46M | -572.00K | 241.82M |
Broncus Holding Corp. Technical Analysis
Negative
2.36
Price Trends
0.97
Negative
1.24
Negative
1.97
Negative
Market Momentum
-0.09
Positive
29.21
Positive
13.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.97, and above the 200-day MA of 1.97, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 29.21 is Positive, neither overbought nor oversold. The STOCH value of 13.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.
Broncus Holding Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$481.49M | 4.51 | 16.21% | 4.94% | 16.46% | 50.51% | |
59 Neutral | HK$2.97B | 57.50 | 2.07% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$334.92M | -3.84 | -20.20% | ― | -51.87% | 38.90% | |
44 Neutral | HK$11.33B | 33.32 | 6.07% | ― | -3.62% | ― | |
43 Neutral | HK$333.10M | -2.03 | -11.54% | ― | ― | ― | |
43 Neutral | HK$22.61B | -84.92 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:2216
Broncus Holding Corp.
0.59
-1.46
-71.22%
HK:0853
MicroPort Scientific
6.48
-2.28
-26.03%
HK:1612
Vincent Medical Holdings Limited
0.73
0.26
56.99%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.12
1.20
20.27%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
23.52
7.36
45.54%
HK:2297
Rainmed Medical Limited
0.24
0.04
22.00%
Broncus Holding Corp. Corporate Events
Broncus Ends Share Subscription Deals, Sees No Material Impact
May 26, 2026
Broncus Holding Corporation has terminated previously announced share subscription agreements with two investors, entering into termination agreements with each subscriber on May 26, 2026, after trading hours. The subscriptions are now null and vo...
Broncus shareholders back all AGM resolutions, update articles of association
May 14, 2026
Broncus Holding Corporation reported that all resolutions proposed at its 14 May 2026 annual general meeting were duly passed by shareholders via poll voting. Investors approved the 2025 audited financial statements, reappointed Ernst Young as au...
Broncus Holding Sets 2026 AGM, Seeks Share Issuance Mandate and Board Renewals
Apr 20, 2026
Broncus Holding Corporation has called its annual general meeting for May 14, 2026, in Hangzhou, where shareholders will review and adopt the audited consolidated financial statements for the year ended December 31, 2025, along with the directors&...
Broncus Holding Delays Shareholder Circular on Major Acquisition
Apr 14, 2026
Broncus Holding Corporation has announced a delay in sending a shareholder circular related to a major transaction involving a further acquisition of shares in a target company. The circular, which will include details of the acquisition, financia...
Broncus Deepens Lung Disease Push as Revenue Plunges on One-Off Hit
Mar 31, 2026
Broncus Holding Corporation reported a sharp downturn in 2025 revenue, largely due to a one-off sales return, which pushed the group into a gross loss and widened its annual loss despite maintaining a sizable cash position. The financial setback c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.